HPΒCD CYCLODEXTRIN DERIVATIVE OPENS NEW AVENUES FOR TREATING ISCHEMIC STROKE IN THE ELDERLY
A recent study has revealed the significant role of 2-Hydroxypropyl-β-Cyclodextrin (HPβCD) in treating ischemic stroke in aged subjects. The research, employing systematic plasma biomarker profiling, has for the first time elucidated the molecular mechanism by which HPβCD promotes long-term functional recovery after stroke through regulating lipid metabolism and suppressing neuroinflammation.
In this study focusing on aged models of ischemic stroke, HPβCD demonstrated therapeutic functions that extend beyond those of a conventional drug delivery vehicle. Researchers discovered that HPβCD effectively promotes cholesterol efflux and metabolic clearance, significantly reducing plasma levels of cholesterol, sphingolipids, and long-chain fatty acids, while simultaneously increasing cholesterol metabolites such as 27-hydroxycholesterol and 7-HOCA. This comprehensive regulation of the lipid metabolic network provides a novel approach for alleviating post-stroke neuroinflammation.
The study further revealed that HPβCD effectively clears lipid fragments accumulated in immune cells, suppressing the formation of "foam-like cells" and blocking the vicious cycle of inflammatory signaling triggered by pro-inflammatory oxylipids. This unique mechanism enables HPβCD to show remarkable advantages in promoting long-term neurological functional recovery, offering new hope for treating elderly stroke patients.
The research not only confirms the direct therapeutic efficacy of HPβCD as an active pharmaceutical agent but also opens new pathways for the application of cyclodextrin-based molecules in treating neurological disorders. Researchers noted that given HPβCD's excellent biocompatibility and clearly defined therapeutic mechanisms, it holds promise for developing innovative therapies for the recovery phase of stroke.
This study marks an important transition of cyclodextrin from a traditional drug delivery carrier to a biologically active molecule with independent therapeutic functions, providing new research directions and development strategies for cerebrovascular disease treatment.
